No evidence of association between PTSD, cancer risk
the ONA take:
According to a new study published in the European Journal of Epidemiology, researchers from Boston University School of Medicine in Boston, Massachusetts, have found that post-traumatic stress disorder (PTSD) is not a risk factor for developing cancer.
For the study, researchers included all Danish-born residents of Denmark from 1995 to 2011. During that time, PTSD was diagnosed in 4,131 people.
Researchers included all malignant neoplasms, hematologic malignancies, immune-related cancers, smoking- and alcohol-related cancers, and cancers at all other sites as main outcomes. Results showed that there were no associations between PTSD and nearly all cancer diagnoses examined.
This study is the largest study to date evaluating PTSD as a predictor of various cancer types. The large sample size and long study duration allowed researchers to examine associations that had previously not been analyzed.
Post-traumatic stress disorder is not a risk factor for developing cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|